This article has Open Peer Review reports available.
Breast cancer histology and receptor status characterization in Asian Indian and Pakistani women in the U.S. - a SEER analysis
© Kakarala et al; licensee BioMed Central Ltd. 2010
Received: 1 October 2009
Accepted: 11 May 2010
Published: 11 May 2010
Recent reports suggest increase in estrogen receptor (ER), progesterone receptor (PR) negative breast cancer yet little is known about histology or receptor status of breast cancer in Indian/Pakistani women.in the U.S.
We examined the United States National Cancer Institute's Surveillance Epidemiology and End Results (SEER) Cancer program to assess: a) frequency of breast cancer by age, b) histologic subtypes, c) receptor status of breast cancer and, d) survival in Indians/Pakistanis compared to Caucasians. There were 360,933 breast cancer cases diagnosed 1988-2006. Chi-Square analyses and Cox proportional hazards models, to estimate relative risks for breast cancer mortality after adjusting for confounders, were performed using Statistical Analysis Software 9.2.
Among Asian Indian/Pakistani breast cancer patients, 16.2% were < 40 yrs. old compared to 6.23% in Caucasians (p < 0.0001). Asian Indian women had more invasive ductal carcinoma (69.1 vs. 65.7%, p < 0.0001), inflammatory cancer (1.4% vs. 0.8, p < 0.0001) and less invasive lobular carcinoma (4.2% vs. 8.1%, p < 0.0001) than Caucasians. Asian Indian/Pakistani women had more ER/PR negative breast cancer (30.6% vs. 21.8%, p = 0.0095) than Caucasians. Adjusting for stage at diagnosis, age, tumor grade, nodal status, and histology, Asian Indian/Pakistani women's survival was similar to Caucasians, while African Americans' was worse.
Asian Indian/Pakistani women have higher frequency of breast cancer (particularly in age < 40), ER/PR negative invasive ductal and inflammatory cancer than Caucasians.
Breast cancer is the most frequently diagnosed cancer in females in the United States, affecting 1 in 8 women . Worldwide, the incidence of breast cancer varies from 3.9/100,000 in Mozambique to as high as 101.1/100,000 in the U.S [2–5]. Geographic variation in breast cancer incidence can be attributed to racial and genetic differences, cultural differences, as well as environmental exposures that vary throughout the world [5, 6]. Recent profiling work demonstrates that breast cancer is not one homogenous disease but consists of at least 5 distinct molecular subtypes with different treatment options and prognoses [7–12].
Overall incidence of breast cancer is declining in the United States in the last decade [6, 13]. However, the incidence of the biologically aggressive estrogen receptor (ER) negative, progesterone receptor (PR) negative breast cancer in women younger than 40 has been increasing in African Americans in the U.S., Nigerian, Chinese, Vietnamese, and Taiwanese populations [14–16]. Recent reports from India and Pakistan suggest an important increase in the incidence of breast cancer and specifically ER, PR negative breast cancer among these populations [16–19]. ER, PR negative breast cancer, of which 50% is also Her2Neu receptor negative (triple negative), is biologically aggressive, resistant to conventional cytotoxic chemotherapy treatment, and is associated with reduced survival compared to other subtypes of breast cancer [20–23].
Cancer incidence studies in Asian Indians and Pakistanis in India and Pakistan as well as emigrants to various countries including Canada, United States, Singapore, United Kingdom have documented a rise in breast cancer in premenopausal Indian and Pakistani women (younger than 40) compared to local Caucasian women [24–33]. Yet very little is known about the specific histologic subtypes or receptor status of breast cancer in women of Indian/Pakistani origin in the U.S. [34–38]. Understanding frequency of occurrence of specific breast cancer subtypes and associated risk factors in Indians/Pakistanis may elucidate breast cancer prevention, screening and treatment strategies tailored to the unique risk of this ethnic group.
We, therefore, explored whether analysis of United States National Cancer Institute's Surveillance Epidemiology and End Results (SEER) Program would: a) indicate a disproportionately high frequency of occurrence of breast cancer in Asian Indian/Pakistani women younger than 40 yrs (premenopausal age) compared to Caucasian females, b) provide data on specific histologic subtypes of breast cancer (eg. invasive ductal, inflammatory or lobular carcinoma), and c) molecular subtypes of breast cancer by receptor status in Asian Indian and Pakistani women in the United States and, 4) the impact of these subtypes on breast cancer specific survival. In this exploratory analysis, we examined demographic characteristics such as age and marital status and biological variables such as histology, estrogen and progesterone receptor status and in situ versus invasive disease as predictive variables for disease outcome and survival.
Subjects were 360,933 females, identified as Caucasian, African American, Hispanic or Indian/Pakistani, diagnosed with breast cancer between 1988 and 2006. Information regarding these subjects was obtained from the population-based SEER database in a case listing session. The SEER program collects information about all incident cancer cases including patient demographics, tumor site, stage at diagnosis, first course of treatment and annual follow up for vital status (SEER website: http://seer.cancer.gov/about/). Currently, 18 population-based registries cover 26% of the United States population. Overall, the combined registries are comparable to the rest of the United States population with regard to poverty and education levels, but are slightly more urban and contain a higher proportion of foreign-born individuals. For the purposes of this analysis, data from 6 SEER sites with high proportion of Indian/Pakistani women were used. These 6 sites are: Atlanta--Georgia, Connecticut, California (Los Angeles, San Francisco-Oakland, San Jose-Monterey, and greater California), Metropolitan Detroit--Michigan, New Jersey, and Seattle-Puget Sound--Washington. In the SEER database, histological type of tumor is coded using International Classification of Diseases for Oncology, Third Edition (ICD-O) codes. The corresponding ICD-O morphology codes for breast cancers (Site and Morphology code = 'Breast') were selected: 8530 (inflammatory), 8522-8524 (mixed), 8100, 8500, 8501, 8503, 8521 and 8523 (ductal), and 8520 (lobular). Two behavior codes were also selected: 2 (in situ) and 3 (invasive). For the purposes of this analysis, a categorical variable was created, with categories for each histological type and behavior. Variables of interest included age at diagnosis, marital status, registry site, AJCC stage, tumor markers (ER and PR), vital status and survival time (months). Population denominators were not available for the Indian/Pakistani population in SEER or in United States Census data, so these results represent frequencies, not rates. As these data are de-identified, human investigation approval was not necessary for this project, but all investigators have signed limited-use data agreements to access and analyze SEER data.
Bivariate analyses (PROC FREQ) and multinomial analyses (PROC CATMOD) were implemented using Statistical Analysis Software (SAS) version 9.2. The p-values presented represent comparisons between Caucasian and Indian/Pakistani breast cancer patients. Bivariate analyses compared categorical age at diagnosis, marital status and SEER program site by race. Multinomial analyses compared clinical characteristics (histology, AJCC SEER modified stage, grade, ER/PR status, tumor size and nodal status) by race adjusting for age and SEER program site. For age, we assigned three age categories: age < 40 yrs corresponding to premenopausal, age 40-50 yrs. for perimenopausal and age > 50 for post menopausal age groups. These are empirical groupings and not based upon hormone testing to establish menopausal status. Tumor size was categorized as < 1 cm, 1 - 4 cm and > 4 cm.
Hormone Receptor Status Analysis
Estrogen receptor was available for 50.5% and progesterone receptor status was available for 49.8% of all breast cancer cases, including in situ ductal or lobular carcinoma (n = 204), invasive ductal (n = 817), invasive lobular (n = 50) and inflammatory breast cancer (n = 16) in Asian Indian/Pakistani females (n = 1087). The proportion of missing data did not differ between Caucasian, Indian/Pakistani, Hispanic and African-American breast cancer patients.
Data from all 6 SEER registries were used for survival analyses. We chose to analyze from 1988 forward because prior to 1988 Asian Indians and Pakistanis were identified only as "Other Asians". Cox proportional hazards models were used to estimate relative risks (RRs) and 95% Confidence Intervals for mortality from breast cancer after adjusting for relevant confounders including AJCC SEER modified stage, histology, behavior, age at diagnosis and SEER program site. A minimum survival time of 2 months was used in selecting cases in order to exclude those diagnosed only at autopsy or those who may have died before pursuing treatment. Non Hispanic Caucasians served as the reference group for relative risk comparisons. All tests were two tailed and p values < 0.05 were considered statistically significant.
Frequency of Breast Cancer in Asian Indians/Pakistanis
Age at diagnosis, marital status and survival of women with breast cancer, 6 SEER program sites, 1988-2006, by ethnicity
n = 300,494
n = 1,350
n = 40,647
n = 18,442
Premenopausal (age < 40)
Perimenopausal (age 40-50)
Postmenopausal (age > 50)
SEER Program Site
Seattle (Puget Sound)
Mean Survival in Months (SD)
Breast Cancer Stage at Diagnosis in Asian Indians/Pakistanis
Percentage of women diagnosed with stage IV or metastatic disease was similar in Asian Indians/Pakistanis compared to Caucasians (4.9 vs. 4.5%). African American and Hispanic women had significantly higher percentage of women presenting with stage III (11.9% and 9.6% versus 7.0%, p < 0.01) compared to Caucasian women. African American women also had the highest percent of stage IV disease (8.1% compared to 4.5% in Caucasians, p < 0.01).
Breast Cancer Histology and Receptor Status in Asian Indians/Pakistanis
Histology and receptor status of breast cancer in women in the 6 SEER program sites diagnosed between 1988-2006 by ethnicity
Estrogen Receptor (ER)
Progesterone Receptor (PR)
Stage at diagnosis, tumor grade, primary tumor size and nodal status by ethnicity in 6 SEER program sites between 1988-2006.*
Primary Tumor Size
< 1 cm
1 -- 4 cm
> 4 cm
# of nodes positive
Breast Cancer Specific Survival in Asian Indians/Pakistanis
Disease-specific five- year survival using Cox-proportional hazards adjusted for SEER site
Univariate HR (95% C.I.)
3.08 (2.905 -- 3.26)
2.80 (2.63 -- 2.98)
5.41 (5.12 -- 5.71)
3.47 (2.48 -- 4.86)
0.73 (0.70 -- 0.77)
0.95 (0.70 -- 1.28)
1.03 (1.00 -- 1.06)
1.43 (1.13 -- 1.80)
1.66 (1.62 -- 1.69)
1.59 (1.37 -- 1.85)
0.95 (0.91 -- 0.99)
0.72 (0.52 -- 0.98)
0.82 (0.70 -- 0.96)
0.45 (0.11 -- 1.79)
1.39 (1.37 -- 1.41)
2.00 (1.75 -- 2.29)
Asian Indians/Pakistanis are one of the fastest growing ethnic groups in the United States and have a higher frequency of breast cancer than Caucasians [26, 33]. Our analysis of breast cancer diagnoses using the SEER database for cases diagnosed from 1988-2006 finds a disproportionately high occurrence rate of breast cancer in Asian Indian/Pakistani women younger than 40 yrs. compared to Caucasians. It is possible the overall age distribution of Asian Indian/Pakistani women is younger compared to the other racial/ethnic groups in the United States, resulting in a disproportionate breakdown by age. This could be due to immigration patterns, as the Indian population reflects the rapid increases in young immigrants in the latter half of the 20th century. Unfortunately, immigration data were not available in SEER, but our results suggest the need for future studies to address this question. However, these findings are consistent with similar high rates observed among south Asians or Indians in Singapore, United Kingdom, Malaysia, Canada and in Indians in India [25, 26, 33, 34, 39–41]. We were unable to examine trends over time using the SEER program due to the relatively small number of cases diagnosed every year for Asian Indians and Pakistanis, however at least one study shows a rise in breast cancer incidence rates in Asian Indians over time .
Over the past decade, the biology of breast cancer has been redefined into groups of distinct biological subtypes. Each subtype presents with specific clinical, pathological and molecular phenotypes associated with diverse natural histories, therapeutic implications and prognoses [8, 42–47]. Previously published studies of breast cancer in Asian Indians did not examine the frequency of specific histologic subtypes of breast cancer: invasive ductal, lobular and inflammatory carcinoma of the breast. Each of these subtypes has a different biologic behavior and prognosis [11, 48, 49]. Inflammatory breast cancer, for example, is the most aggressive histologic subtype with worse hazard ratio for 5 year survival in our own multivariate analysis [50–52] and occurs more frequently among Asian Indians compared to Caucasians in our analysis. Lobular invasive carcinoma may present with bilateral disease and recur many years from primary disease presentation. The most common histology in both Caucasians and Asian Indians/Pakistanis, invasive ductal carcinoma is usually unilateral and risk of recurrence decreases as time elapses from primary diagnosis [49, 53, 54]. Differences in behavior of distinct breast cancer histologies determine whether a patient receives breast conservation or aggressive surgical treatment, sentinel node or complete axillary dissection. Systemic treatment such as duration of hormone therapy, targeted therapy for Her2Neu positive disease and followup patterns also differ for different breast cancer subtypes . Our SEER analysis shows that invasive ductal carcinoma is more frequently diagnosed in Asian Indian/Pakistani women compared to Caucasian women while diagnosis of lobular carcinoma is correspondingly lower.
A higher proportion of breast cancer in Asian Indian/Pakistani women compared to Caucasians (30.6% vs. 21.8%, p < 0.0095) in the SEER database was ER and PR negative. It must be noted that individuals for whom receptor status was missing were excluded from that analysis and missing data was comparable in both groups. Reports in Asian Indians in India and the United Kingdom also document high rates of ER, PR negative breast cancer [34, 36]. Interestingly, when receptor status was examined by age, we found that this difference was driven by increased percentage of ER/PR negative disease in 40-50 yr olds and those older than 50, rather than by younger aged women.
We were unable to examine Her2 Neu receptor status as this variable is only recently being collected by the SEER program. However, pathologic assessments of tumors over time have found the particularly aggressive, and least treatable, triple negative (ER, PR and Her2Neu negative) or basal breast cancer molecular subtype to be common in Asian Indians [38, 56]. This subtype of breast cancer is more common among BRCA1 gene mutation carriers, however, known BRCA1 and BRCA2 mutations do not seem to explain the triple negative cancer in Indian women [57–59]. Stage at diagnosis is critical in breast cancer as early stage cancer is curable while more advanced stages are not [28, 60]. Asian Indian/Pakistani women were diagnosed at significantly more advanced stages of breast cancer than Caucasian women suggesting a need to raise awareness of screening recommendations in this ethnic group.
In conclusion, Asian Indian and Pakistani women in the US had more ER and PR negative tumors than their Caucasian counterparts. Invasive ductal carcinoma is the most common histology. Inflammatory cancer is also more common in Asian Indians/Pakistanis than Caucasians. Given the limited treatment options for receptor negative breast cancer and poor prognosis, it is important to encourage screening and early diagnosis measures such as annual clinical breast exams for these women.
- Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 2009, 59 (4): 225-249. 10.3322/caac.20006.View ArticlePubMedGoogle Scholar
- Bolufer P, Molina R, Ruiz A, Hernandez M, Vazquez C, Lluch A: Estradiol receptors in combination with neu or myc oncogene amplifications might define new subtypes of breast cancer. Clin Chim Acta. 1994, 229 (1-2): 107-122. 10.1016/0009-8981(94)90233-X.View ArticlePubMedGoogle Scholar
- La Vecchia C, Franceschi S, Lucchini F, Levi F: International Variations and Trends in the Incidence of Breast Cancer in Older Women. Cancer Control. 1994, 1 (4): 327-333.PubMedGoogle Scholar
- Marugame T, Katanoda K: International comparisons of cumulative risk of breast and prostate cancer, from cancer incidence in five continents Vol. VIII. Jpn J Clin Oncol. 2006, 36 (6): 399-400. 10.1093/jjco/hyl049.View ArticlePubMedGoogle Scholar
- Rosen M, Lundin A, Nystrom L, Rutqvist LE, Stenbeck M, Talback M: [Incidence and mortality of breast cancer during a 25-year period. International and regional comparisons]. Lakartidningen. 2000, 97 (4): 294-299.PubMedGoogle Scholar
- Morabia A, Costanza MC: Reproductive factors and incidence of breast cancer: an international ecological study. Soz Praventivmed. 2000, 45 (6): 247-257. 10.1007/BF01591687.View ArticlePubMedGoogle Scholar
- Boyd ZS, Wu QJ, O'Brien C, Spoerke J, Savage H, Fielder PJ, Amler L, Yan Y, Lackner MR: Proteomic analysis of breast cancer molecular subtypes and biomarkers of response to targeted kinase inhibitors using reverse-phase protein microarrays. Mol Cancer Ther. 2008, 7 (12): 3695-3706. 10.1158/1535-7163.MCT-08-0810.View ArticlePubMedGoogle Scholar
- Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, et al: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006, 295 (21): 2492-2502. 10.1001/jama.295.21.2492.View ArticlePubMedGoogle Scholar
- Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO: Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008, 14 (5): 1368-1376. 10.1158/1078-0432.CCR-07-1658.View ArticlePubMedGoogle Scholar
- Onitilo AA, Engel JM, Greenlee RT, Mukesh BN: Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res. 2009, 7 (1-2): 4-13. 10.3121/cmr.2009.825.View ArticlePubMedPubMed CentralGoogle Scholar
- Sims AH, Howell A, Howell SJ, Clarke RB: Origins of breast cancer subtypes and therapeutic implications. Nat Clin Pract Oncol. 2007, 4 (9): 516-525. 10.1038/ncponc0908.View ArticlePubMedGoogle Scholar
- Sorlie T: Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur J Cancer. 2004, 40 (18): 2667-2675. 10.1016/j.ejca.2004.08.021.View ArticlePubMedGoogle Scholar
- Couris CM, Polazzi S, Olive F, Remontet L, Bossard N, Gomez F, Schott AM, Mitton N, Colonna M, Trombert B: Breast cancer incidence using administrative data: correction with sensitivity and specificity. J Clin Epidemiol. 2009, 62 (6): 660-666. 10.1016/j.jclinepi.2008.07.013.View ArticlePubMedGoogle Scholar
- Deapen D, Liu L, Perkins C, Bernstein L, Ross RK: Rapidly rising breast cancer incidence rates among Asian-American women. Int J Cancer. 2002, 99 (5): 747-750. 10.1002/ijc.10415.View ArticlePubMedGoogle Scholar
- Lee SY, Jeong SH, Kim YN, Kim J, Kang DR, Kim HC, Nam CM: Cost-effective mammography screening in Korea: high incidence of breast cancer in young women. Cancer Sci. 2009, 100 (6): 1105-1111. 10.1111/j.1349-7006.2009.01147.x.View ArticlePubMedGoogle Scholar
- Lin CH, Liau JY, Lu YS, Huang CS, Lee WC, Kuo KT, Shen YC, Kuo SH, Lan C, Liu JM, et al: Molecular subtypes of breast cancer emerging in young women in Taiwan: evidence for more than just westernization as a reason for the disease in Asia. Cancer Epidemiol Biomarkers Prev. 2009, 18 (6): 1807-1814. 10.1158/1055-9965.EPI-09-0096.View ArticlePubMedGoogle Scholar
- Adebamowo CA, Famooto A, Ogundiran TO, Aniagwu T, Nkwodimmah C, Akang EE: Immunohistochemical and molecular subtypes of breast cancer in Nigeria. Breast Cancer Res Treat. 2008, 110 (1): 183-188. 10.1007/s10549-007-9694-5.View ArticlePubMedGoogle Scholar
- Ihemelandu CU, Leffall LD, Dewitty RL, Naab TJ, Mezghebe HM, Makambi KH, Adams-Campbell L, Frederick WA: Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival. J Surg Res. 2007, 143 (1): 109-118. 10.1016/j.jss.2007.03.085.View ArticlePubMedGoogle Scholar
- Nichols HB, Trentham-Dietz A, Love RR, Hampton JM, Hoang Anh PT, Allred DC, Mohsin SK, Newcomb PA: Differences in breast cancer risk factors by tumor marker subtypes among premenopausal Vietnamese and Chinese women. Cancer Epidemiol Biomarkers Prev. 2005, 14 (1): 41-47.PubMedGoogle Scholar
- Akiyama F, Iwase H: Triple negative breast cancer: clinicopathological characteristics and treatment strategies. Breast Cancer. 2009, 16 (4): 252-3. 10.1007/s12282-009-0140-x.View ArticlePubMedGoogle Scholar
- Alli E, Sharma VB, Sunderesakumar P, Ford JM: Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. Cancer Res. 2009, 69 (8): 3589-3596. 10.1158/0008-5472.CAN-08-4016.View ArticlePubMedPubMed CentralGoogle Scholar
- Bouchalova K, Cizkova M, Cwiertka K, Trojanec R, Hajduch M: Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009, 153 (1): 13-17.View ArticlePubMedGoogle Scholar
- Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM: The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007, 13 (8): 2329-2334. 10.1158/1078-0432.CCR-06-1109.View ArticlePubMedGoogle Scholar
- Gajalakshmi P, Natarajan TG, Selvi Rani D, Thangaraj K: A novel BRCA1 mutation in an Indian family with hereditary breast/ovarian cancer. Breast Cancer Res Treat. 2007, 101 (1): 3-6. 10.1007/s10549-006-9267-z.View ArticlePubMedGoogle Scholar
- Ghumare SS, Cunningham JE: Breast cancer trends in Indian residents and emigrants portend an emerging epidemic for India. Asian Pac J Cancer Prev. 2007, 8 (4): 507-512.PubMedGoogle Scholar
- Goggins WB, Wong G: Cancer among Asian Indians/Pakistanis living in the United States: low incidence and generally above average survival. Cancer Causes Control. 2009, 20 (5): 635-643. 10.1007/s10552-008-9275-x.View ArticlePubMedGoogle Scholar
- Hebert JR, Ghumare SS, Gupta PC: Stage at diagnosis and relative differences in breast and prostate cancer incidence in India: comparison with the United States. Asian Pac J Cancer Prev. 2006, 7 (4): 547-555.PubMedGoogle Scholar
- Jack RH, Davies EA, Moller H: Breast cancer incidence, stage, treatment and survival in ethnic groups in South East England. Br J Cancer. 2009, 100 (3): 545-550. 10.1038/sj.bjc.6604852.View ArticlePubMedPubMed CentralGoogle Scholar
- Kamath SK, Murillo G, Chatterton RT, Hussain EA, Amin D, Mortillaro E, Peterson CT, Alekel DL: Breast cancer risk factors in two distinct ethnic groups: Indian and Pakistani vs. American premenopausal women. Nutr Cancer. 1999, 35 (1): 16-26. 10.1207/S1532791416-26.View ArticlePubMedGoogle Scholar
- Murthy NS, Agarwal UK, Chaudhry K, Saxena S: A study on time trends in incidence of breast cancer - Indian scenario. Eur J Cancer Care (Engl). 2007, 16 (2): 185-186. 10.1111/j.1365-2354.2006.00761.x.View ArticleGoogle Scholar
- Raju GC, Naraynsingh V: Breast cancer in West Indian women in Trinidad. Trop Geogr Med. 1989, 41 (3): 257-260.PubMedGoogle Scholar
- Rao R, Kuerer H, Cristofanilli M, Brigilio K, Shukla S, Rao M, Krishnamurthy S: Breast cancer in the asian Indian population of the United States: a call for screening and education. Breast J. 2008, 14 (4): 402-403. 10.1111/j.1524-4741.2008.00613.x.View ArticlePubMedGoogle Scholar
- Rastogi T, Devesa S, Mangtani P, Mathew A, Cooper N, Kao R, Sinha R: Cancer incidence rates among South Asians in four geographic regions: India, Singapore, UK and US. Int J Epidemiol. 2008, 37 (1): 147-160. 10.1093/ije/dym219.View ArticlePubMedGoogle Scholar
- Dey S, Boffetta P, Mathews A, Brennan P, Soliman A, Mathew A: Risk factors according to estrogen receptor status of breast cancer patients in Trivandrum, South India. Int J Cancer. 2009, 125 (7): 1663-70. 10.1002/ijc.24460.View ArticlePubMedGoogle Scholar
- Kumar VL, Srivastava A, Singhal R, Kumar V: Immunoreactive estrogen receptor in breast tumor and adjacent tissue: association with clinicopathological characteristics in Indian population. J Surg Oncol. 2005, 89 (4): 251-255. 10.1002/jso.20211.View ArticlePubMedGoogle Scholar
- Navani S, Bhaduri AS: High incidence of oestrogen receptor negative progesterone receptor positive phenotype in Indian breast cancer: fact or fiction?. Indian J Pathol Microbiol. 2005, 48 (2): 199-201.PubMedGoogle Scholar
- Seshadri R, Shah PN: Steroid receptors in breast cancer in Indian women. Anticancer Res. 1984, 4 (6): 403-407.PubMedGoogle Scholar
- Shet T, Agrawal A, Nadkarni M, Palkar M, Havaldar R, Parmar V, Badwe R, Chinoy RF: Hormone receptors over the last 8 years in a cancer referral center in India: what was and what is?. Indian J Pathol Microbiol. 2009, 52 (2): 171-174. 10.4103/0377-4929.48909.View ArticlePubMedGoogle Scholar
- Wu TY, West B, Chen YW, Hergert C: Health beliefs and practices related to breast cancer screening in Filipino, Chinese and Asian-Indian women. Cancer Detect Prev. 2006, 30 (1): 58-66. 10.1016/j.cdp.2005.06.013.View ArticlePubMedGoogle Scholar
- Blesch KS, Davis F, Kamath SK: A comparison of breast and colon cancer incidence rates among native Asian Indians, US immigrant Asian Indians, and whites. J Am Diet Assoc. 1999, 99 (10): 1275-1277. 10.1016/S0002-8223(99)00313-2.View ArticlePubMedGoogle Scholar
- Chakraborty A, Mishra AK, Soni A, Regina T, Mohil R, Bhatnagar D, Bhatnagar A, Chintamani C, Sharma PC, Saxena S: Vitamin D receptor gene polymorphism(s) and breast cancer risk in north Indians. Cancer Detect Prev. 2009, 32 (5-6): 386-394. 10.1016/j.canep.2009.04.012.View ArticlePubMedGoogle Scholar
- Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 2007, 109 (9): 1721-1728. 10.1002/cncr.22618.View ArticlePubMedGoogle Scholar
- Bertolo C, Guerrero D, Vicente F, Cordoba A, Esteller M, Ropero S, Guillen-Grima F, Martinez-Penuela JM, Lera JM: Differences and molecular immunohistochemical parameters in the subtypes of infiltrating ductal breast cancer. Am J Clin Pathol. 2008, 130 (3): 414-424. 10.1309/J3QV9763DYPV338D.View ArticlePubMedGoogle Scholar
- Del Casar JM, Martin A, Garcia C, Corte MD, Alvarez A, Junquera S, Gonzalez LO, Bongera M, Garcia-Muniz JL, Allende MT, et al: Characterization of breast cancer subtypes by quantitative assessment of biological parameters: relationship with clinicopathological characteristics, biological features and prognosis. Eur J Obstet Gynecol Reprod Biol. 2008, 141 (2): 147-152. 10.1016/j.ejogrb.2008.07.021.View ArticlePubMedGoogle Scholar
- Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G, Delorenzi M, Piccart M, Sotiriou C: Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res. 2008, 14 (16): 5158-5165. 10.1158/1078-0432.CCR-07-4756.View ArticlePubMedGoogle Scholar
- Hannemann J, Kristel P, van Tinteren H, Bontenbal M, van Hoesel QG, Smit WM, Nooij MA, Voest EE, Wall van der E, Hupperets P, et al: Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy. Br J Cancer. 2006, 95 (10): 1334-1341. 10.1038/sj.bjc.6603449.View ArticlePubMedPubMed CentralGoogle Scholar
- Harris LN, Broadwater G, Lin NU, Miron A, Schnitt SJ, Cowan D, Lara J, Bleiweiss I, Berry D, Ellis M, et al: Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res. 2006, 8 (6): R66-10.1186/bcr1622.View ArticlePubMedPubMed CentralGoogle Scholar
- Ivshina AV, George J, Senko O, Mow B, Putti TC, Smeds J, Lindahl T, Pawitan Y, Hall P, Nordgren H, et al: Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res. 2006, 66 (21): 10292-10301. 10.1158/0008-5472.CAN-05-4414.View ArticlePubMedGoogle Scholar
- Rosenberg LU, Magnusson C, Lindstrom E, Wedren S, Hall P, Dickman PW: Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: a case-control study. Breast Cancer Res. 2006, 8 (1): R11-10.1186/bcr1378.View ArticlePubMedPubMed CentralGoogle Scholar
- Ben Hamida A, Labidi IS, Mrad K, Charafe-Jauffret E, Ben Arab S, Esterni B, Xerri L, Viens P, Bertucci F, Birnbaum D, et al: Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: prominent expression of P-cadherin. BMC Cancer. 2008, 8: 28-10.1186/1471-2407-8-28.View ArticlePubMedPubMed CentralGoogle Scholar
- Bertucci F, Finetti P, Rougemont J, Charafe-Jauffret E, Cervera N, Tarpin C, Nguyen C, Xerri L, Houlgatte R, Jacquemier J, et al: Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Cancer Res. 2005, 65 (6): 2170-2178. 10.1158/0008-5472.CAN-04-4115.View ArticlePubMedGoogle Scholar
- Van Laere SJ, Eynden Van den GG, Auwera Van der I, Vandenberghe M, van Dam P, Van Marck EA, van Golen KL, Vermeulen PB, Dirix LY: Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling. Breast Cancer Res Treat. 2006, 95 (3): 243-255. 10.1007/s10549-005-9015-9.View ArticlePubMedGoogle Scholar
- Chan SW, LaVigne KA, Port ER, Fey JV, Brogi E, Borgen PI, Cody HS: Does the benefit of sentinel node frozen section vary between patients with invasive duct, invasive lobular, and favorable histologic subtypes of breast cancer?. Ann Surg. 2008, 247 (1): 143-149. 10.1097/SLA.0b013e3181581f41.View ArticlePubMedGoogle Scholar
- Wong SL, Chao C, Edwards MJ, Carlson DJ, Laidley A, Noyes RD, McGlothin T, Ley PB, Tuttle T, Schadt M, et al: Frequency of sentinel lymph node metastases in patients with favorable breast cancer histologic subtypes. Am J Surg. 2002, 184 (6): 492-498. 10.1016/S0002-9610(02)01057-7.View ArticlePubMedGoogle Scholar
- Dinshaw KA, Sarin R, Budrukkar AN, Shrivastava SK, Deshpande DD, Chinoy RF, Badwe R, Hawaldar R: Safety and feasibility of breast conserving therapy in Indian women: two decades of experience at Tata Memorial Hospital. J Surg Oncol. 2006, 94 (2): 105-113. 10.1002/jso.20497.View ArticlePubMedGoogle Scholar
- Vyas JJ, Desai PB, Sampat MB, Shinde SR, Rao DN, Sarkar S, Badwe R, Tiwari J, Koppikar A: Observations on Indian node-negative breast cancer patients: a multivariate analysis. J Surg Oncol. 1989, 42 (4): 256-263. 10.1002/jso.2930420411.View ArticlePubMedGoogle Scholar
- Pestonjamasp PH, Mittra I: Analysis of BRCA1 involvement in breast cancer in Indian women. J Biosci. 2000, 25 (1): 19-23. 10.1007/BF02985177.View ArticlePubMedGoogle Scholar
- Saxena S, Chakraborty A, Kaushal M, Kotwal S, Bhatanager D, Mohil RS, Chintamani C, Aggarwal AK, Sharma VK, Sharma PC, et al: Contribution of germline BRCA1 and BRCA2 sequence alterations to breast cancer in Northern India. BMC Med Genet. 2006, 7: 75-10.1186/1471-2350-7-75.View ArticlePubMedPubMed CentralGoogle Scholar
- Saxena S, Szabo CI, Chopin S, Barjhoux L, Sinilnikova O, Lenoir G, Goldgar DE, Bhatanager D: BRCA1 and BRCA2 in Indian breast cancer patients. Hum Mutat. 2002, 20 (6): 473-474. 10.1002/humu.9082.View ArticlePubMedGoogle Scholar
- Keam B, Im SA, Kim HJ, Oh DY, Kim JH, Lee SH, Chie EK, Han W, Kim DW, Moon WK, et al: Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. BMC Cancer. 2007, 7: 203-10.1186/1471-2407-7-203.View ArticlePubMedPubMed CentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/10/191/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.